English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Background  Protein phosphatase 2A ( PP2A ) functions as a tumor suppressor in many cancers. Cancerous inhibitor of protein phosphatase 2A ( CIP2A ) inhibits  PP2A  proteolytic degradation of  c-Myc  and enhances cell growth and tumor formation in several tissues.  CIP2A  expression in acute myeloid leukemia (AML) and its effect on outcome of treatment were not reported in Egyptian patients.    Results  No significant difference was detected in  CIP2A  expression between AML and control groups ( P  = 0.48). However, in AML patients, those with low  CIP2A  expression had a longer median overall survival than those with high expression ( P  = 0.059).  CIP2A  expression was not related to the clinical and laboratory variables and did not affect response to treatment.    Conclusion  High- CIP2A  expression was associated with a trend of shorter overall survival in adult Egyptian AML patients. It might serve as a useful marker to predict poor prognosis.  CIP2A  may represent a potential target for cancer therapy.

Prognostic value of CIP2A gene expression in adult Egyptian acute myeloid leukemia patients